dan 2163 has been researched along with Depression, Involutional in 10 studies
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
Excerpt | Relevance | Reference |
---|---|---|
" Secondary outcomes included psychopathology, remission, all-cause-discontinuation, inefficacy-related discontinuation, and adverse events." | 3.01 | Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. ( Correll, CU; Hagi, K; Kane, JM; Kishimoto, T; Kurokawa, S, 2023) |
" However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 5 (50.00) | 24.3611 |
2020's | 3 (30.00) | 2.80 |
Authors | Studies |
---|---|
Kishimoto, T | 1 |
Hagi, K | 1 |
Kurokawa, S | 1 |
Kane, JM | 1 |
Correll, CU | 1 |
Carstens, L | 1 |
Popp, M | 1 |
Keicher, C | 1 |
Hertrampf, R | 1 |
Weigner, D | 1 |
Meiering, MS | 1 |
Luippold, G | 1 |
Süssmuth, SD | 1 |
Beckmann, CF | 1 |
Wunder, A | 1 |
Grimm, S | 1 |
Liu, Y | 1 |
Admon, R | 1 |
Mellem, MS | 1 |
Belleau, EL | 1 |
Kaiser, RH | 1 |
Clegg, R | 1 |
Beltzer, M | 1 |
Goer, F | 1 |
Vitaliano, G | 1 |
Ahammad, P | 1 |
Pizzagalli, DA | 1 |
Carta, MG | 1 |
Paribello, P | 1 |
Nardi, AE | 1 |
Preti, A | 1 |
Hou, YC | 1 |
Lai, CH | 1 |
Chen, J | 1 |
Gao, K | 1 |
Kemp, DE | 1 |
Komossa, K | 1 |
Depping, AM | 1 |
Gaudchau, A | 1 |
Kissling, W | 1 |
Leucht, S | 1 |
Agarwal, SM | 1 |
Rao, NP | 1 |
Venkatasubramanian, G | 1 |
Behere, RV | 1 |
Varambally, S | 1 |
Gangadhar, BN | 1 |
Montgomery, SA | 1 |
Fric, M | 1 |
Laux, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effects of Dopamine on Reward Processing[NCT01253421] | Phase 1 | 159 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
Early Life Stress and Depression: Molecular and Functional Imaging Approaches[NCT01701258] | Phase 1 | 153 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.2231 |
MDD-placebo | -0.0391 |
HC-amisulpride | -0.0938 |
HC-placebo | 0.0582 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after Reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.5783 |
MDD-placebo | -0.2673 |
HC-amisulpride | -0.33 |
HC-placebo | 0.1955 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between caudate and dorsal anterior cingulate cortex (dACC) in response to reward outcomes (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.3628 |
MDD-placebo | 0.3881 |
HC-amisulpride | 0.2992 |
HC-placebo | 0.6192 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.2446 |
MDD-placebo | 0.0736 |
HC-amisulpride | 0.1356 |
HC-placebo | 0.2182 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.9377 |
MDD-placebo | 0.1578 |
HC-amisulpride | 0.4018 |
HC-placebo | 0.954 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between nucleus accumbens (NAcc) and mid-cingulate cortex (MCC) in response to reward outcomes. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.4375 |
MDD-placebo | 0.324 |
HC-amisulpride | 0.4846 |
HC-placebo | 0.4877 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from penalties during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from penalty trials. (NCT01253421)
Timeframe: administered after scan
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.2428 |
MDD-placebo | 0.29 |
HC-amisulpride | 0.2207 |
HC-placebo | 0.2391 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from rewards during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from reward trials. (NCT01253421)
Timeframe: administered after scan
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.6271 |
MDD-placebo | 0.7575 |
HC-amisulpride | 0.823 |
HC-placebo | 0.7545 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation (beta) after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.6338 |
MDD-placebo | 0.1709 |
HC-amisulpride | -0.14 |
HC-placebo | 0.436 |
This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session
Intervention | Effect size (Beta) (Mean) |
---|---|
MDD-amisulpride | 0.4969 |
MDD-placebo | 0.3955 |
HC-amisulpride | 0.4169 |
HC-placebo | 0.3808 |
"This is a measure of area under the curve in relation to ground, a measure of total cortisol output, in response to acute stress. The acute stressor was the Maastricht Acute Stress Test (MAST). The area under the curve includes all 5 cortisol measures, with one measure before the stressor and the other four measures collected after the stressor. Given that the cortisol data were positively skewed, the cortisol measures were normalized via a log transformation prior to calculating the area under the curve.~Area under the curve with respect to ground (AUCG) is calculated AUC_g=(((cort2_log + cort1_log) * cort_t1_time) / 2)+(((cort3_log+cort2_log)*cort_t2_time)/2)+(((cort4_log+cort3_log)*cort_t3_time)/2)+(((cort5_log+cort4_log)*cort_t4_time)/2). Cort_logs are the log transformed cortisol output data (ng/ml) and the cort_times are the time spans in between each cortisol assessment." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | [log (ng/ml)]*min (Mean) |
---|---|
Control Group | 156.58 |
MDD Group | 186.78 |
CSA/RES Group | 152.13 |
CSA/MDD Group | 179.16 |
This statistic shows the impact of the stress manipulation on the participant's salivary cortisol output. Saliva samples were collected at 5 distinct time points throughout the study session. The first saliva sample (Cort 1) was collected when the participant began the eeg session. The second (Cort 2)was taken at the end of the acute stressor. The third (Cort 3) was taken approximately fifteen minutes after the second. The fourth (Cort 4) was taken approximately ten minutes after the third. The fifth (Cort 5) was taken approximately 40 minutes after the fourth. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | ng/ml (Mean) | ||||
---|---|---|---|---|---|
Cort1 | Cort2 | Cort3 | Cort4 | Cort5 | |
Control Group | 9.80 | 9.11 | 15.55 | 12.89 | 7.07 |
CSA/MDD Group | 14.19 | 8.63 | 14.31 | 14.22 | 11.01 |
CSA/RES Group | 10.15 | 9.51 | 10.75 | 8.99 | 7.41 |
MDD Group | 12.53 | 12.28 | 15.23 | 16.30 | 10.34 |
"Utilizing 11C-altropane during positron emission tomography (PET) scanning allows us to measure dopamine active transporter (DAT) binding potential.~Our outcome measure is Nondisplacable Binding Potential (BPND). BPND refers to the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in tissue.~*Higher BPND scores indicate greater binding potential" (NCT01701258)
Timeframe: 1 hour PET scan (Session 3)
Intervention | Ratio (Mean) | ||
---|---|---|---|
Caudate | Putamen | Accumbens | |
Control Group | 3.191 | 3.361 | 2.159 |
CSA/MDD Group | 3.216 | 3.318 | 2.149 |
CSA/RES Group | 3.175 | 3.241 | 2.103 |
MDD Group | 3.161 | 3.359 | 2.103 |
"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward cues during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Drug & fMRI Session (Session 2)
Intervention | beta weight (slope) (Mean) | |||||
---|---|---|---|---|---|---|
Caudate Response to Reward Cues | Caudate Response to Neutral Cues | Putamen Response to Reward Cues | Putamen Response to Neutral Cues | Accumbens Response to Reward Cues | Accumbens Response to Neutral Cues | |
Control-amisulpride | .200 | .222 | .608 | .455 | .401 | .016 |
Control-placebo | .468 | .185 | .663 | .518 | .480 | .120 |
CSA/MDD-amisulpride | .514 | .254 | .550 | .550 | .692 | .385 |
CSA/MDD-placebo | .054 | -.243 | .468 | .357 | .255 | .040 |
CSA/RES-amisulpride | .511 | .050 | .745 | .493 | .679 | -.123 |
CSA/RES-placebo | .079 | -.370 | .419 | .240 | .310 | -.381 |
MDD-amisulpride | .403 | .047 | .698 | .384 | .351 | -.111 |
MDD-placebo | .608 | .156 | .814 | .621 | .428 | .140 |
"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward feedback during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Session 2 (fMRI session)
Intervention | beta weight (slope) (Mean) | |||||
---|---|---|---|---|---|---|
Caudate Response to Reward Feedback | Caudate Response to Neutral Feedback | Putamen Response to Reward Feedback | Putamen Response to Neutral Feedback | Accumbens Response to Reward Feedback | Accumbens Response to Neutral Feedback | |
Control-amisulpride | -.613 | -.793 | -.533 | -.375 | .074 | -.503 |
Control-placebo | -.273 | -.105 | -.131 | .164 | .069 | .109 |
CSA/MDD-amisulpride | -.101 | -.233 | -.018 | -.021 | -.158 | .010 |
CSA/MDD-placebo | .040 | -.608 | .063 | -.418 | .839 | -.332 |
CSA/RES-amisulpride | -.197 | -.501 | -.087 | -.142 | -.046 | -.079 |
CSA/RES-placebo | -.905 | -.959 | -.304 | -.276 | -.713 | -.819 |
MDD-amisulpride | -.819 | -.865 | -.031 | -.229 | -.554 | -.456 |
MDD-placebo | -.773 | -.733 | -.357 | -.108 | -.215 | -.039 |
"EEG was recorded during the probabilistic reward task (the PRT task). Participants completed the Probabilistic Reward Task (PRT) twice throughout the experiment, once before stress and once after stress. The stressor was the Maastricht Acute Stress Test (MAST). This statistic shows the effect that childhood sexual abuse (CSA) and diagnosis had on a reward-related positivity EEG component recorded during the PRT, before and after stress.~Higher reward positivity amplitudes indicate a stronger neural response to reward and lower amplitudes indicate a lower neural response to rewards." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | amplitude (microvolts) (Mean) | |
---|---|---|
Pre MAST | Post MAST | |
Control Group | 2.71 | 2.06 |
CSA/MDD Group | 4.15 | 3.90 |
CSA/RES Group | 2.16 | 2.30 |
MDD Group | 4.75 | 4.99 |
The participant's performance on the Probabilistic Reward Task (PRT) was assessed both before and after an acute stressor. The PRT is a behavioral task that measures an individual's ability to learn from rewarding stimuli and incorporate this learning into their response style (response bias). The acute stressor was the Maastricht Acute Stress Test (MAST). The score obtained is a ratio of the number of times participants correctly choose the high reward stimuli versus the low rewarding stimuli. Response bias scores range between -1 and +1. Higher response bias scores indicate a stronger response bias toward high reward stimuli. A negative response bias indicates a stronger bias toward low reward stimuli. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)
Intervention | Ratio (Response Bias Score) (Mean) | |||
---|---|---|---|---|
PRT Block1: Before MAST | PRT Block2: Before MAST | PRT Block1: After MAST | PRT Block2: After MAST | |
Control Group | 0.028 | 0.124 | 0.128 | 0.245 |
CSA/MDD Group | 0.167 | 0.168 | 0.048 | 0.127 |
CSA/RES Group | 0.092 | 0.130 | 0.079 | 0.143 |
MDD Group | 0.117 | 0.155 | 0.078 | 0.128 |
5 reviews available for dan 2163 and Depression, Involutional
Article | Year |
---|---|
Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2023 |
Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Dysthymic Diso | 2019 |
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depr | 2011 |
Second-generation antipsychotics for major depressive disorder and dysthymia.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive | 2010 |
Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.
Topics: Amisulpride; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; D | 2002 |
2 trials available for dan 2163 and Depression, Involutional
Article | Year |
---|---|
Effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing using task-based fMRI in healthy subjects and patients with major depressive disorder - study protocol for a randomized clinical trial.
Topics: Amisulpride; Brain; Depressive Disorder, Major; Healthy Volunteers; Humans; Magnetic Resonance Imagi | 2023 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major | 2020 |
3 other studies available for dan 2163 and Depression, Involutional
Article | Year |
---|---|
Brain morphology changes in a remitted patient with late-onset, drug-naïve, non-psychotic major depressive disorder after amisulpride monotherapy.
Topics: Amisulpride; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Middle Aged; S | 2013 |
Successful treatment of atypical depression with amisulpride: a case report.
Topics: Amisulpride; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Sulpiride; Young Adu | 2012 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |